Investigators from the University of Padua, Italy, University of Bologna, Italy and University/AKH of Vienna, Austria undertook a systematic analysis of neuropathic pain (NP) clinical research as reported in Dovepress. NP represents an enormous burden for patients, caregivers and society. Many NP patients are substantially disabled for years. Due to its chronicity, severity and unpredictability, NP is difficult to treat.
Tapentadol is a central-acting oral analgesic with combined opioid and noradrenergic properties, which make it potentially suitable for a wide range of pain conditions, particularly whenever a NP component is present or cannot be excluded.
During randomized controlled trials, tapentadol proved to be effective in relieving NP in diabetic peripheral neuropathy and in chronic low back pain. In observational studies, tapentadol reduced NP in chemotherapy-induced peripheral neuropathies, blood and solid cancers, and the NP component in neck pain and Parkinson’s disease. The investigators’ narrative review sought to provide clinicians with a broad overview of tapentadol effects on NP.
Ulderico Freo, University of Padua
Patrizia Rumualdi, University of Bologna
Hans G. Kress, Medical University/AKH of Vienna